TrialLeukemia2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
G A Horne et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
45 papers cite it
this paperpooled itcites it